title: Basic fibroblast growth factor reduces scar formation in acute incisional wounds.
abstract: In order to identify a means to reduce scar formation of the skin after incision, this study examined the effect of local administration of basic fibroblast growth factor (bFGF) in humans. bFGF was administered to a sutured wound immediately after an operation. The drug was injected once into the dermis of the margins of wounds using a 27G needle or rinsing after performing dermostitches. The lengths of the treated wounds varied from 1 to 32 cm, and the subjects were 2-86 years old. Sutured wounds after excision of skin tumors from the face, trunk, and limbs and sutured wounds such as those at the donor sites of full-thickness skin grafts were treated with low-dose bFGF injections (0.1 microg/cm wound; Group 2), high-dose bFGF injections (1 microg/cm wound; Group 3), and rinsed with high-dose bFGF (1 microg/cm wound; Group 4). No patient treated with bFGF had hypertrophic scars, while some patients had hypertrophic or very wide scars in the control group (Group 1), and the ratios of minimum scarring of Group 2 (p<0.001), Group 3 (p<0.0001), and Group 4 (p<0.0001) were statistically significantly higher than those of Group 1. Postoperative administration of bFGF inhibited hypertrophic scarring and widening of remaining scars without any serious side effects.
authors.affiliation: Department of Dermatology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan. ichiro@sapmed.ac.jp
authors.forename: Ichiro
authors.initials: I
authors.lastname: Ono
authors.forename: Yoshikiyo
authors.initials: Y
authors.lastname: Akasaka
authors.forename: Risa
authors.initials: R
authors.lastname: Kikuchi
authors.forename: Akiko
authors.initials: A
authors.lastname: Sakemoto
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kamiya
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Yamashita
authors.forename: Kowichi
authors.initials: K
authors.lastname: Jimbow
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D002921:Cicatrix / Q000503:physiopathology / Q000517:prevention & control*; D017439:Cicatrix, Hypertrophic / Q000503:physiopathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018307:Neoplasms, Squamous Cell / Q000601:surgery; D012878:Skin Neoplasms / Q000601:surgery; D013536:Suture Techniques; D014945:Wound Healing / Q000502:physiology*
chemical_list: D016222:Fibroblast Growth Factor 2